Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate HELP committee adds staffer

Executive Summary

Sen. Mike Enzi, R-Wyo., ranking member of the Senate Health, Education, Labor and Pensions Committee, announces Chuck Clapton has joined the committee's minority staff as health policy director. His previous experience includes extensive work in the drug reimbursement area. Clapton most recently served as chief health counsel for Republican staff of the House Ways and Means Committee after working as a health care policy advisor for former Speaker Dennis Hastert, R-Ill. (1"The Pink Sheet," April 3, 2006, In Brief). He also served as health counsel to then House Energy & Commerce Committee Chair Billy Tauzin, R-La., during the drafting of the Medicare Modernization Act

You may also be interested in...



Speaker Hastert adds health policy advisor

House Energy & Commerce Committee Chief Health Counsel Chuck Clapton joins the office of Speaker Dennis Hastert (R-Ill.) as policy adviser for healthcare and social security issues. Clapton was with the E&C Committee when Billy Tauzin, now CEO of PhRMA, served as chairman. Clapton has supported FDA, even when the agency faced strong criticism from others for its handling of drug safety. Following the COX-2 inhibitor fallout on Capitol Hill, Clapton stated that FDA was doing a "very good job" and that there was no need for "sweeping or comprehensive reforms" (1"The Pink Sheet" April 11, 2005, p. 15)...

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief. 

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel